Kymera Therapeutics and Sanofi Report First Patient Dosing with KT-474 in P-II Trial for the Treatment of Atopic Dermatitis
Shots:
- The first patient was dosed in the P-II (ADVANTA) trial evaluating the safety & efficacy of KT-474 (SAR444656) vs PBO in patients with moderate to severe AD. Following the P-I evaluation, Sanofi was held responsible for conducting further development & commercialization of KT-474
- As per the terms of Kymera & Sanofi’s Jul 2020 agreement, Kymera received $15M as a milestone payment for dosing the first AD patient. Earlier in Oct 2023, Kymera was granted $40M as a milestone payment for dosing the first HS patient with KT-474 in a P-II study
- Kymera had published the results from the P-I evaluation of KT-474, an oral IRAK4 degrader being developed for IL-1R/TLR-driven complex inflammatory diseases, in ‘Nature Medicine’
Ref: Kymera Therapeutics | Image: Kymera Therapeutics
Related News:- Kymera Therapeutics Receives the US FDA’s Fast Track Designation to KT-333 for Cutaneous and Peripheral T-Cell Lymphoma
PharmaShots! Your go-to media platform for customized news ranging for multiple indications. For more information connect with us at connect@pharmashots.com
Click here to read the full press release
Tags
Kritika is a content writer at PharmaShots. She is interested in covering recent innovations from the pharma & MedTech industry. She covers news related to Product approvals, clinical trial results, and updates. She can be contacted at connect@pharmashots.com.
